CME Group (CME) General Counsel John Marchese Receives Restricted Stock Award

What Happened
John Clifford Marchese, Senior Managing Director and General Counsel of CME Group, was granted 784 restricted shares under the CME Group Omnibus Stock Plan on 2026-09-15 (total value reported $215,671 at $275.09/share). Over 2026-09-15 and 2026-09-16 he surrendered 241 shares (in several lots) to the company to satisfy tax withholding obligations, with the surrendered shares valued at about $66,180 in total (prices ranged $272.46–$275.09). The grant is a restricted stock award (not an open-market purchase) and the surrendered shares were used for tax withholding (not a market sale).

Key Details

• Transaction dates and prices:
  • 2026-09-15: Award of 784 shares at $275.09/share (value $215,671).
  • 2026-09-15: Surrenders of 43, 47, 57 and 50 shares at $275.09/share (total ~$54,192).
  • 2026-09-16: Surrender of 44 shares at $272.46/share (~$11,988).
  • Total surrendered: 241 shares; total value surrendered ≈ $66,180.
• Shares owned after transaction: Not disclosed in the provided filing excerpt.
• Footnotes of note:
  • F1: The 784-share award is restricted stock vesting in four equal annual installments, granted under the Omnibus Stock Plan. The award amount was determined based on his role as of Sept 1, 2026, prior to his promotion effective Sept 11, 2026.
  • F2: The surrendered shares were used to satisfy tax withholding obligations in connection with the vesting of previously granted restricted stock.
• Filing timeliness: The Form 4 was filed on 2026-09-17 for transactions dated 2026-09-15–09-16; no late filing was indicated in the provided data.

Context
This filing shows a standard restricted-stock award and routine share surrenders to cover tax withholding. The award will vest over time (four-year schedule) subject to continued service; it is not an immediate open-market purchase. Footnote F1 also notes a promotion-related equity grant is expected in March 2027 and will be reported separately.